|
[Related PubMed/MEDLINE]
Total Number of Papers: 111
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2022 |
Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9-10 clinical localized prostate cancer. |
Conv RT, DMFS, HDR boost, HDRT, IMRT, PCSM |
| 2 |
2022 |
Grade migration and important prognostic factors in a pathology specimen for radical radiotherapy in prostate cancer patients. |
BC |
| 3 |
2022 |
Stereotactic Radiotherapy and Androgen Deprivation Therapy for Localized Prostate Cancer: A Retrospective Mono-institutional Experience. |
ADT, IIEF, IPSS, OS, PROs, SRT, V-MAT IGRT |
| 4 |
2022 |
The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521. |
CRP, HR, IL, RT, RTOG |
| 5 |
2021 |
Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. |
DFS |
| 6 |
2021 |
Novel Prognostic Index of High-Risk Prostate Cancer Using Simple Summation of Very High-Risk Factors. |
BT, DMSF, EBRT, PCSM, VHR |
| 7 |
2021 |
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. |
ADT, HRT, MFS, OS, PCa |
| 8 |
2021 |
Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy. |
HDR, OS, PSS |
| 9 |
2021 |
Ultrahypofractionated Proton Radiation Therapy in the Treatment of Low and Intermediate-Risk Prostate Cancer-5-Year Outcomes. |
IMPT, PBS, PSA |
| 10 |
2020 |
A systematic review of salvage focal therapies for localised non-metastatic radiorecurrent prostate cancer. |
ADT, PSA, RP, SBT, WW |
| 11 |
2019 |
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. |
ADT, GS, PCa, PSA, RT |
| 12 |
2019 |
Evaluation of neutrophil-to-lymphocyte ratio as a prognostic indicator in a Singapore cohort of patients with clinically localized prostate cancer treated with prostatectomy. |
AUC, CSS, MFS, NLR, OS |
| 13 |
2019 |
Impact of a dominant intraprostatic lesion (DIL) boost defined by sextant biopsy in permanent I-125 prostate implants on biochemical disease free survival (bDFS) and toxicity outcomes. |
DIL |
| 14 |
2019 |
Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography. |
BF, LNs, PCa, PET, PSA, PSMA, SBRT |
| 15 |
2019 |
Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial. |
PCa, UHRT |
| 16 |
2018 |
Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience. |
PCa |
| 17 |
2018 |
Non-Whole-Gland High-Intensity Focused Ultrasound vs Whole-Gland High-Intensity Focused Ultrasound for Management of Localized Prostate Cancer: 1-Year Oncological and Functional Outcomes. |
HIFU, IIEF-5, IPSS, mpMRI, PSA |
| 18 |
2018 |
Stereotactic body radiation therapy (SBRT) for high-risk prostate cancer: Where are we now? |
BT, HDR, HR, SBRT |
| 19 |
2018 |
Tailored postoperative treatment of prostate cancer: final results of a phase I/II trial. |
EORTC, HT, OS, PSA, RP, RT |
| 20 |
2017 |
Adaptive cone-beam CT planning improves long-term biochemical disease-free survival for 125I prostate brachytherapy. |
BF, CBCT, CI, HR, NCCN, PCa, TRUS |
| 21 |
2017 |
Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer patients. |
ADT, DMFS, PTV |
| 22 |
2017 |
Comparison on efficacy of radical prostatectomy versus external beam radiotherapy for the treatment of localized prostate cancer. |
CSS, EBRT, HR, IMRT, OR, OS, RP |
| 23 |
2017 |
Effects of dose-escalated radiotherapy in combination with long-term androgen deprivation on prostate cancer. |
ADT, cRFS, OS, RT |
| 24 |
2017 |
Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer. |
BCF, CEFS, CI, FS-HIFU, HIFU, IQR, PET, PSA, SD |
| 25 |
2017 |
Heterogeneity of Outcomes in D'Amico Intermediate-Risk Prostate Cancer Patients after Radical Prostatectomy: Influence of Primary and Secondary Gleason Score. |
bGS, IR |
| 26 |
2017 |
Impact of a rectal and bladder preparation protocol on prostate cancer outcome in patients treated with external beam radiotherapy. |
cDFS, GS, MVA, PCa, PCSS, UVA |
| 27 |
2017 |
Prognostic factors in prostate cancer patients treated by radical external beam radiotherapy. |
cDFS, CSS, CT, GS, RT |
| 28 |
2017 |
Studying the efficacy of escalated dose conformal radiation therapy in prostate carcinoma - Pakistan experience. |
EBRT, PSA |
| 29 |
2017 |
Very high-risk prostate cancer: stratification by outcomes of radiotherapy and long-term androgen deprivation therapy. |
ADT, cRFS, CSS, EBRT, VHR |
| 30 |
2016 |
External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. |
cDFS, CSOS, EBRT, GI, GS, GU |
| 31 |
2016 |
Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer after permanent prostate brachytherapy with a review of the literature. |
F-CTV, GI, GU, PSA, PTV |
| 32 |
2016 |
Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. |
--- |
| 33 |
2016 |
High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes. |
ADT, HT, IQR |
| 34 |
2016 |
Proposal for magnetic resonance imaging-guided salvage radiotherapy for prostate cancer. |
CT, HR, MRI, PSA, SRT |
| 35 |
2016 |
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after primary radiotherapy failure. |
HDR-BT, OS |
| 36 |
2016 |
Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry. |
GI, SBRT |
| 37 |
2016 |
Ten-year outcomes using low dose rate brachytherapy for localised prostate cancer: An update to the first Australian experience. |
CTCAE, PSA |
| 38 |
2015 |
Definitive radiotherapy plus regional hyperthermia for high-risk and very high-risk prostate carcinoma: Thermal parameters correlated with biochemical relapse-free survival. |
HT, RT |
| 39 |
2015 |
Definitive radiotherapy plus regional hyperthermia for high-risk and very high-risk prostate carcinoma: Thermal parameters correlated with biochemical relapse-free survival. |
HT, RT |
| 40 |
2015 |
Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: a comparison of Australian series. |
ADT, DE-IG-IMRT, EBRT, HR, IR, MFS, PCaSS |
| 41 |
2015 |
Neo-adjuvant hormone therapy for non-metastatic prostate cancer: a systematic review and meta-analysis of 5,194 patients. |
cDFS, CI, NHT, OR, OS, PCa, PSM, RCTs, RP |
| 42 |
2015 |
Postoperative radiotherapy in prostate cancer: Analysis of prognostic factors in a series of 282 patients. |
GS, HT, PSA, RT |
| 43 |
2014 |
Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer. |
PSA |
| 44 |
2014 |
External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer. |
ADT, DMFS, EBRT, LDR, OS |
| 45 |
2014 |
Long-term outcomes from dose-escalated image-guided intensity-modulated radiotherapy with androgen deprivation: encouraging results for intermediate- and high-risk prostate cancer. |
ADT, DE, IG-IMRT, IMRT |
| 46 |
2014 |
Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study. |
EPIC, SBRT |
| 47 |
2014 |
The clinical significance of persistent cancer cells on prostate biopsy after high-dose-rate brachytherapy boost for intermediate-risk prostate cancer. |
PSA |
| 48 |
2013 |
Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry. |
ADT, COLD, cT3, EBRT, RP |
| 49 |
2013 |
Does neoadjuvant androgen deprivation therapy before primary whole gland cryoablation of the prostate affect the outcome? |
CRYO, NADT |
| 50 |
2013 |
Four-year outcomes of hypofractionated high-dose-rate prostate brachytherapy and external beam radiotherapy. |
BED, HDR, IMRT, PSA |
| 51 |
2013 |
Fourteen-year oncological and functional outcomes of high-intensity focused ultrasound in localized prostate cancer. |
HIFU, PCa |
| 52 |
2013 |
Intensity-modulated radiotherapy versus radical prostatectomy in patients with localized prostate cancer: long-term follow-up. |
CSS, IMRT, MOC, OS, PCa, PSA, RP |
| 53 |
2013 |
May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy? |
BF, CSS, DMFS, EBRT, GS, nPSA, PADT |
| 54 |
2013 |
Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis. |
ADT, CSS, DMFS, EBRT, GS, OS |
| 55 |
2013 |
[High-intensity focussed ultrasound in low-risk prostate cancer - oncological outcome and postinterventional quality of life of an inexperienced therapy centre in comparison with an experienced therapy centre]. |
HIFU, PCa, TURP |
| 56 |
2012 |
Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy. |
--- |
| 57 |
2012 |
Initial brazilian experience in the treatment of localized prostate cancer using a new generation cryotechnology: feasibility study. |
--- |
| 58 |
2012 |
Low-dose rate brachytherapy of the prostate in elderly patients. |
ASTRO, NCCN, OS, RTOG |
| 59 |
2012 |
Outcomes of salvage prostate cryotherapy stratified by pre-treatment PSA: update from the COLD registry. |
COLD, PSA |
| 60 |
2012 |
Preliminary results of intensity-modulated radiation therapy with helical tomotherapy for prostate cancer. |
ADT, GI, GU, HT |
| 61 |
2012 |
Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. |
BF, BRT, nPSA |
| 62 |
2012 |
Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. |
PSA, PSADT |
| 63 |
2011 |
A retrospective analysis after low-dose-rate prostate brachytherapy with permanent (125)I seed implant: clinical and dosimetric results in 70 patients. |
ASTRO, GS, NCCN |
| 64 |
2011 |
Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. |
ADT, PORT, WPRT |
| 65 |
2011 |
Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir. |
ADT, OS, PCSS, PSA, RT |
| 66 |
2011 |
High-intensity focused ultrasound as salvage therapy for patients with recurrent prostate cancer after external beam radiation, brachytherapy or proton therapy. |
EBRT, HIFU, PSA |
| 67 |
2011 |
Impact of race on biochemical disease recurrence after prostate brachytherapy. |
ADT, EBRT, FFBF, PSA |
| 68 |
2011 |
Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. |
CI, COLD, PSA |
| 69 |
2011 |
Prognostic impact of abdominal adiposity, waist circumference and body mass index in patients with intermediate-risk prostate cancer treated with radiotherapy. |
BMI, GS, nPSA, SAT, WC |
| 70 |
2011 |
Robotic radical prostatectomy: a critical analysis of the impact on cancer control. |
RALP |
| 71 |
2011 |
The pattern of prostate cancer local recurrence after radiation and salvage cryoablation. |
--- |
| 72 |
2010 |
A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. |
ART, LVI, PSA, RP, RT, SM, SRT |
| 73 |
2010 |
Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease? |
LTAD, PSA, STAD |
| 74 |
2010 |
Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. |
IQR, PCa, PSA |
| 75 |
2010 |
Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. |
BTV, DSS, IGRT-DE, mets, RG, SPECT/CT |
| 76 |
2010 |
Treatment for intermediate and high-risk prostate cancer: controversial issues and the role of hyperthermia. |
AST, HT, OS, QoL, RT |
| 77 |
2009 |
Definitive conformal radiotherapy for localized prostate cancer: a long-term follow-up study. |
AD, HR, IR, LR, OS |
| 78 |
2009 |
Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy? |
ART, NADT, OS, RP, RT, SRT |
| 79 |
2009 |
External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004. |
AD, OS, RT |
| 80 |
2009 |
Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study. |
HDR-BT |
| 81 |
2009 |
Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial. |
ADT, PRPH-PSA, RT |
| 82 |
2009 |
Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. |
IMRT, PSA, RP |
| 83 |
2009 |
Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. |
PORT, WPRT |
| 84 |
2009 |
[Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions]. |
RT |
| 85 |
2008 |
Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us? |
ASTRO, LTAD, NB, PB, PCa, PSA, RT, STAD, TRUS |
| 86 |
2008 |
Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. |
ASTRO, HRQoL, PSA, QoL |
| 87 |
2007 |
(125)I monotherapy using D90 implant doses of 180 Gy or greater. |
--- |
| 88 |
2007 |
Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. |
ASTRO, BTVs, EBRT, PSA, RF, RG, SI, SPECT/CT |
| 89 |
2007 |
Definitive conformal radiotherapy for localized high-risk prostate cancer: a long-term follow-up study with PSA course. |
--- |
| 90 |
2007 |
High-grade prostatic intraepithelial neoplasia is an independent predictor of outcome after radical prostatectomy. |
HGPIN, PSA, RP |
| 91 |
2007 |
Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives. |
AD, ASTRO, SD-EBRT |
| 92 |
2007 |
Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer. |
BMI, DSS, OS, RT |
| 93 |
2007 |
Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. |
DSS, OS, PSAV |
| 94 |
2007 |
Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. |
CRYO, DSS, EBRT, GI, OS |
| 95 |
2006 |
Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation? |
AAD, ICRU, NAD |
| 96 |
2005 |
Dosimetry and cancer control after low-dose-rate prostate brachytherapy. |
bRFS, LDR-PB |
| 97 |
2005 |
Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation. |
CI, EBRT, NAHT, PSA |
| 98 |
2005 |
Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. |
AAD, AD, NAD |
| 99 |
2005 |
[Dose escalation with three dimensional conformal radiotherapy for prostate cancer: more is better?]. |
AAD, NAD |
| 100 |
2004 |
Combination conformal radiotherapy and radioimmunoguided transperineal 103Pd implantation for patients with intermediate and unfavorable risk prostate adenocarcinoma. |
BTVs, EBRT, HT, RF |
|
A Search Service for Abbreviation / Long Form
